Brian E. Toki
Impact in
-
- Monoclonal and Polyclonal Antibodies Research
- Oncology top 1%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 10
- Oncology 9
- HER2/EGFR in Cancer Research 8
- Peptidase Inhibition and Analysis 2
- Cancer Treatment and Pharmacology 2
- Co-authors
- Peter D. Senter (11 shared papers)Alan F. Wahl (6 shared papers)Charles G. Cerveny (6 shared papers)Damon L. Meyer (5 shared papers)Svetlana O. Doronina (4 shared papers)Joseph A. Francisco (4 shared papers)Clay B. Siegall (2 shared papers)Dana F. Chace (2 shared papers)
- Journals
- Bioconjugate Chemistry (4 papers)Journal of Medicinal Chemistry (2 papers)Cancer Research (2 papers)Molecular Cancer Therapeutics (1 paper)Journal of Natural Products (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
Brian E. Toki
15 papers receiving 2.9k citations
Brian E. Toki's Hit Papers
Peers
Comparison fields: 5 of 86
- Radiology, Nuclear Medicine and Imaging 1.4k
- Oncology 1.6k
- Pathology and Forensic Medicine 325
- Immunology and Allergy 109
- Organic Chemistry 562
Countries citing papers authored by Brian E. Toki
This map shows the geographic impact of Brian E. Toki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian E. Toki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian E. Toki more than expected).
Fields of papers citing papers by Brian E. Toki
This network shows the impact of papers produced by Brian E. Toki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian E. Toki. The network helps show where Brian E. Toki may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian E. Toki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Development of potent monoclonal antibody auristatin conjugates for cancer therapy Hit paper breakdown → | 2003 | 963 |
| 2 | cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Hit paper breakdown → | 2003 | 725 |
| 3 | 2005 | 419 | |
| 4 | 1998 | 223 | |
| 5 | 2013 | 153 | |
| 6 | 2006 | 127 | |
| 7 | 2013 | 105 | |
| 8 | 2009 | 86 | |
| 9 | 1999 | 73 | |
| 10 | 2002 | 71 | |
| 11 | 2016 | 51 | |
| 12 | 1999 | 33 | |
| 13 | 2006 | 32 | |
| 14 | 2009 | 21 | |
| 15 | Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy | 2004 | 3 |
About Brian E. Toki
Brian E. Toki is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, Organic Chemistry and Pharmacology, having authored 15 papers that have together received 3.1k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (8 papers), Glycosylation and Glycoproteins Research (4 papers), Click Chemistry and Applications (3 papers), Peptidase Inhibition and Analysis (2 papers), Cancer Treatment and Pharmacology (2 papers), Chemical Synthesis and Analysis (2 papers) and Synthesis and biological activity (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.4k citations), Oncology (1.6k citations), Pathology and Forensic Medicine (325 citations), Immunology and Allergy (109 citations) and Organic Chemistry (562 citations). Brian E. Toki has collaborated with scholars based in United States and Germany. Frequent co-authors include Peter D. Senter, Alan F. Wahl, Charles G. Cerveny, Damon L. Meyer, Svetlana O. Doronina, Joseph A. Francisco, Clay B. Siegall, Dana F. Chace, Tim D. Bovee and Brian A. Mendelsohn. Their work appears in journals such as Bioconjugate Chemistry, Journal of Medicinal Chemistry, Cancer Research, Molecular Cancer Therapeutics and Journal of Natural Products.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.